CJC-1295 / Ipamorelin Peptide Therapy Cost in Utah

CJC-1295 / Ipamorelin Peptide Therapy in Utah costs $357 to $1,224 in 2026, with a state-wide median of $607. Pricing varies by metro - typically $607 in Salt Lake City and $607 in Salt Lake City. Utah pricing is 2% above the national average.

Salt Lake City typically has the lowest cjc-1295 / ipamorelin peptide therapy pricing in Utah, with a median of $607 (1.02x national average). Mid-size markets generally run lower than major coastal or wealthy suburban areas.

Salt Lake City typically has the highest cjc-1295 / ipamorelin peptide therapy pricing in Utah, with a median of $607 (1.02x national average). Larger metro areas with higher cost of living and more specialty providers tend to command premium pricing.

CJC-1295/Ipamorelin is not covered by any US health insurance plan. There is no FDA-approved version. Tesamorelin (FDA-approved alternative) may be covered for HIV-associated lipodystrophy indication; off-label use is generally not covered.

Utah pricing is 2% above the national average. The state cost index is 1.02x the national average. Higher-cost states include California, New York, Massachusetts, and Washington DC; lower-cost states include Oklahoma, Mississippi, Kentucky, and Indiana.

CJC-1295 (with DAC) and Ipamorelin cannot legally be compounded by 503A pharmacies for human use in the United States as of 2026, following FDA reclassification in 2023. No FDA-approved version exists. Compliant access pathways are essentially limited to clinical-necessity exception cases or transition to alternatives like Sermorelin or Tesamorelin.

CJC-1295 with DAC (Drug Affinity Complex) has an extended half-life of 6-8 days, requiring only once or twice weekly injection. CJC-1295 without DAC (also called Modified GRF 1-29) has a half-life of 30 minutes, requiring daily injection. The FDA reclassification applies to both formulations.

The combination stimulates the body's pituitary to produce more endogenous growth hormone through two different mechanisms. Animal and limited human studies show increased growth hormone pulses and IGF-1 levels. Marketed effects (improved sleep, recovery, body composition, anti-aging) exceed the published clinical evidence base.

In 2022-2023, before FDA reclassification, the combination protocol from licensed 503A compounding pharmacies through mens health and longevity clinics typically cost $350-$1,200 per month depending on dose, vial concentration, and pharmacy. Premium concierge clinics could exceed $1,500/month.

Sermorelin is the most common legal alternative still 503A-compoundable, similar mechanism (GHRH analog) but less potent than CJC-1295/Ipamorelin combination. Tesamorelin (Egrifta) is FDA-approved on-label for HIV-associated lipodystrophy and prescribed off-label for similar GH-releasing effects, but expensive at $1,500-$2,000/month. None of these duplicate the exact CJC-1295/Ipamorelin protocol.